Treatments for metastatic renal-cell carcinoma have evolved rapidly in the past decade, and since 2006, targeted therapies have been the cornerstone of treatments, with pazopanib or sunitinib leading to objective responses in 24–31% of patients.1 Deep tumour responses have been described as a surrogate measure for overall survival in patients with renal-cell carcinoma.2 However, because these are rarely achieved with current standard first-line targeted therapies, novel tyrosine-kinase inhibitors (TKIs) are being tested.
Original Article: [Comment] Aiming for complete responses in renal-cell carcinoma